RecruitingRecruiting
Precision Depression Adalimumab Trial
NCT07845604 · University of Pennsylvania
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
An Precision Immunopsychiatric Pharmacological Probe of Adalimumab as an Anti-depressant
About this study
This is a 57-day intensive longitudinal study of 60 adult subjects with Major Depressive Disorder and elevated baseline tumor necrosis factor (TNF) levels. A triple-blind, placebo-controlled pharmacological investigation of adalimumab as an adjunctive medication to escitalopram will be conducted to determine anti-depressant efficacy of adalimumab. Patients will be screened for depression, health concerns, and a minimum of 1.5 pg/mL TNFa. It is hypothesized that adalimumab will lead to improved treatment outcomes (specifically somatic/neurovegetative symptoms). It is hypothesized that, if more symptoms than somatic/neurovegetative respond, they will do so less quickly than somatic/neurovegetative symptoms.
Enrolled participants will be randomized in a 2:1 ratio to adjunctive adalimumab or placebo in addition to the participant's regular dose of escitalopram each day (both conditions). Patients will be matched for sex. Enrolled patients will attend 4 clinic visits, at which point they will receive injections of adalimumab or placebo from the study psychiatrist (Day 1, 15, 29, and 43 for injections), in addition to clinician-assessed measures. Daily self-report assessments of depression symptoms will be collected for 57 days.
Eligibility criteria
Inclusion Criteria:
* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged 18+ years
* Meet DSM-5 criteria for Major Depressive Disorder
* baseline serum TNF-alpha (average of two samples in the same week) greater than 1.5 pg/mL
* Taking a steady dose of Lexapro (escitalopram) for at least 4 weeks
* Ability to take oral medication and physician-administered subcutaneous injection and be willing to adhere to the study protocol
* For females of reproductive potential: use of highly effective contraception for at least 1 month
* Access to a phone or computer with a camera
Exclusion Criteria:
1. Pregnant or breastfeeding
2. Active, chronic or recurrent infection
3. Known malignancy
4. Current use of immune modulating medications
5. Immunocompromised, current autoimmune condition or history of severe immune condition (e.g., history of cancer, HIV/AIDS)
6. History of, or positive test for, Hepatitis B surface antigen or core antibody positivity or tuberculosis (TB)
7. Congestive heart failure
8. History of demyelinating disease (multiple sclerosis (MS), optic neuritis, Guillain-Barre syndrome)
9. History of seizure disorder
10. Symptomatic hyponatremia
11. Monoamine oxidase inhibitors (MAOI) use within 14 days
12. Recent use of Rituxan (rituximab)
13. Concomitant use of:
1. Immunosuppressants
2. Kineret (anakinra)
3. Orencia (abatacept)
4. Remicade (infliximab)
5. Enbrel (etanercept)
6. Cimzia (certolizumab pegol)
7. Simponi (golimumab)
8. Imuran (azathioprine)
9. Purinethol (6-mercaptopurine)
10. Linezolid
11. IV methylene blue
12. Pimozide
13. Antiplatelet agents
14. Strong anticoagulants (e.g. warfarin, large doses of NSAIDs)
15. Other SSRIs, SNRIs, tryptophan
14. Clinically relevant substance use disorder
15. Known allergic reactions to components of adalimumab and/or escitalopram
16. Treatment with another investigational drug or other intervention while participating in the study
Study design
Enrollment target: 60 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-11
Estimated completion: 2031-09
Last updated: 2026-11-12
Interventions
Drug: Adalimumab Biosimilars InjectionOther: Placebo
Primary outcomes
- • Change from baseline in individual somatic, affective, and motivational depressive symptoms, as measured by the Quick Inventory of Depressive Symptomatology (QIDS) (From start of trial to the end of study (Day 57))
Sponsor
Daniel Moriarity · other
With: Brain & Behavior Research Foundation
Contacts & investigators
ContactDaniel P Moriarity, PhD · contact · dmori@upenn.edu · (484) 808-5930
InvestigatorDaniel P. Moriarity, PhD · principal_investigator, University of Pennsylvania
All locations (1)
University of PennsylvaniaRecruiting
Philadelphia, Pennsylvania, United States